AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $123.97
- 52-wk high
- $145.82
- High
- $123.97
- 52-wk low
- $102.07
- Low
- $121.09
- Prev close
- $124.34
- Mkt cap
- $7.76B
- P/E
- 22.4x
- Volume
- 383.0K
- Fwd P/E
- 19.7x
- Beta
- 0.38
- Div yield
- 1.52%
- P/S
- 2.0x
- P/B
- 3.0x
- Profit margin
- +9.2%
- Op margin
- +12.5%
- ROE
- +13.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 6.0% above what analysts expected.
Earnings per share
$1.34 expected
Reports Oct 29, 2026, in 48 days
EPS expected
$1.46 to $1.49
Revenue expected
6 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $966.0M | $961.1M | $962.7M | $982.9M |
| Cost of what it sold | $668.9M | $673.3M | $701.1M | $706.7M |
| Gross profit | $297.1M | $287.9M | $261.6M | $276.2M |
| What it spent | ||||
| Research and development | $306.4M | $455.2M | $151.3M | $167.6M |
| Sales and admin | $151.1M | $148.8M | $151.3M | $167.6M |
| Other operating costs | -$306.4M | -$455.2M | -$151.7M | -$167.6M |
| Total operating expenses | $151.1M | $148.8M | $151.0M | $167.6M |
| What was left | ||||
| Operating profit | $146.0M | $139.1M | $110.7M | $108.6M |
| Interest on debt | $10.8M | $13.5M | $17.0M | $16.9M |
| Profit before tax | $139.7M | $154.1M | $91.5M | $93.8M |
| Tax | $28.0M | $26.3M | $17.3M | $21.0M |
| Net profit | $111.7M | $127.9M | $74.3M | $72.7M |
| EBITDA | $220.5M | $242.9M | $185.1M | $186.4M |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is mixed
Tone of tracked coverage
Aptar and Aceso Therapeutics Announce Collaboration to Advance Inhaled Antisense Oligonucleotide Therapy for Cystic Fibrosis
NeutralSep 7Aptargroup CHRO Shiela Vinczeller sells $99,732 in company stock By Investing.com
NeutralSep 4Aptargroup CHRO Shiela Vinczeller sells $99,732 in company stock By Investing.com
NeutralSep 4Aptargroup CHRO Shiela Vinczeller sells $99,732 in company stock
NeutralSep 3Aptargroup CHRO Shiela Vinczeller sells $99,732 in company stock By Investing.com
NeutralSep 3AptarGroup CHRO Shiela Vinczeller Sells 765 Shares of Common Stock at $130.37 Average Price
Leans bearishSep 3AptarGroup Names Gael Touya as CEO and Adds Him to Board of Directors
Leans bullishSep 1Aptargroup segment pres., CEO designate Gael Touya sells $500k in shares
NeutralAug 28
Macro
10 macro signals shaping ATR right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results